Prothena Corp Public (PRTA) Non Operating Income (2013 - 2026)
Prothena Corp Public's (PRTA) quarterly Non Operating Income came in at $2.7 million in Q1 2026, down 36.15% year-on-year from $4.2 million in Q1 2025, and up 2.4% quarter-over-quarter from $2.6 million in Q4 2025.
Prothena Corp Public (PRTA) Non Operating Income (2013 - 2026) Analysis & Trends
Prothena Corp Public's Non Operating Income history runs 14 years deep, the most recent figure standing at $2.7 million for Q1 2026.
- On a quarterly basis, Non Operating Income fell 36.15% year-over-year to $2.7 million in Q1 2026; TTM through Mar 2026 was $12.3 million, a 45.98% decrease from a year earlier, with the FY2025 full-year figure at $13.8 million, down 46.12% from the prior year.
- Non Operating Income rose to $2.7 million in Q1 2026 per PRTA's latest filing, from $2.6 million in the prior quarter.
- Across five years, Non Operating Income topped out at $8.5 million in Q3 2023 and bottomed at -$17000.0 in Q1 2022.
- The 5-year median for Non Operating Income is $4.2 million (2025), against an average of $4.6 million.
- Biggest YoY gain for Non Operating Income was 85525.0% in 2022; the steepest drop was 150.0% in 2022.
- Year by year, Non Operating Income stood at $3.4 million in 2022, then jumped by 131.11% to $7.9 million in 2023, then tumbled by 31.67% to $5.4 million in 2024, then slumped by 51.37% to $2.6 million in 2025, then advanced by 2.4% to $2.7 million in 2026.
- Per Business Quant, the three latest PRTA Non Operating Income figures stand at $2.7 million (Q1 2026), $2.6 million (Q4 2025), and $3.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 444,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -8.59 Mn |
| 10 | Prothena Corp Public | 467.80 Mn | 138.33 Mn | - | 2.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.69 Mn |
| Dec 31, 2025 | 2.62 Mn |
| Sep 30, 2025 | 3.33 Mn |
| Jun 30, 2025 | 3.65 Mn |
| Mar 31, 2025 | 4.21 Mn |
| Dec 31, 2024 | 5.40 Mn |
| Sep 30, 2024 | 6.68 Mn |
| Jun 30, 2024 | 6.47 Mn |
| Mar 31, 2024 | 7.09 Mn |
| Dec 31, 2023 | 7.90 Mn |
| Sep 30, 2023 | 8.51 Mn |
| Jun 30, 2023 | 7.60 Mn |
| Mar 31, 2023 | 6.55 Mn |
| Dec 31, 2022 | 3.42 Mn |
| Sep 30, 2022 | 1.92 Mn |
| Jun 30, 2022 | 637,000.00 |
| Mar 31, 2022 | -17,000.00 |
| Dec 31, 2021 | -4,000.00 |
| Sep 30, 2021 | -31,000.00 |
| Jun 30, 2021 | -53,000.00 |